胃癌患者血清中CCL20和CCR6的表达及临床意义

Clinical significance of chemokine CCL20 and its receptor CCR6 expression in patients with gastric cancer

目的 测定趋化因子CCL20及其受体CCR6在胃癌患者的血清中表达,并探讨CCL20和CCR6表达水平与胃癌的发生发展关系.方法 应用荧光定量PCR技术、流式细胞术和酶联免疫吸附法测定50例胃癌患者和30例健康对照者外周血中CCL20和CCR6的mRNA和蛋白表达水平.结果 胃癌患者CCL20和CCR6的mRNA表达均显著高于健康对照组（P〈0.01）;胃癌患者外周血中CCL20和CCR6的蛋白表达分别为（45.4±10.9）pg/mL和（7.11±1.03）%,显著高于健康人的（18.6±4.7）pg/mL和（1.83±0.43）%（P〈0.01）,且其升高程度与胃癌临床分期有明显关系.结论 胃癌患者CCL20和CCR6的表达与胃癌的发生发展存在一定的相关性,可能参与胃癌的发病过程,推测其可能作为胃癌诊断、复发和转移的分子标志物.

Objective To investigate the expression of CCL20 and CCR6 in the patients with gastric cancer and To examine the relationship between chemokine expression and the occurrence and development of Gastric Cancer. Methods Real-time PCR , flow cytometry and ELISA are used to measure the gene transcription and protein expression levels of chemokine CCL20 and CCR6 in the serum of 50 patients with Gastric Cancer and 30 normal controls. Results The gene expression levels CCL20 and CCR6 in Gastric Cancer group are significantly higher than that in healthy controls. The level protein of CCL20 and CCR6 in peripheral blood of patients with gastric cancer are significantly higher than that in healthy peep le[ （45.4 ±10.9） pg/mL vs （18.6±4.7） pg/mL; （7.11 ±1.03%） vs （1.83±0.43%）, P〈0.01. respectively],and the increase significantlyassociated with the clinical stage of Gastric Cancer. Conclusions The method for detecting the expression of CCL20 and CCR6 in patient with Gastric Cancer has been successfully established, and their expression levels were found to be correlated with the occurrence and development of Gastric Cancer. Thus, CCL20 and CCR6 may be involved in the regulatory mechanisms associated with the development of Gastric Cancer, and may be valuable in its diagnosis and prevention.